Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

They may recommend a combination of therapy drugs and alternative treatments. Yes, you have a say in your cancer treatment, including making the decision to delay treatment or not have treatment ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

About the Drugs Below is a detailed analysis of ... Treatment of hormone-refractory prostate cancer, Treatment of BRCA1/2 mutated cancers that demonstrates tolerance (resistance) to currently ...

A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on the appropriate options.

The urine test, called MyProstateScore 2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. The researchers had previously demonstrated that the test was effective in ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...